Christopher Moxham, Ph.D.
February 3, 2021
Chris Moxham, Ph.D. joined Fulcrum in January 2019 as senior vice president of Discovery Research before being promoted to chief scientific officer in January 2021. He has more than two decades of experience in drug discovery. Prior to joining Fulcrum, Chris worked at Eli Lilly and Company where he helped grow the organization’s oncology pipeline, developed critical biopharma and academic partnerships and established a state-of-the-art laboratory facility focused on preclinical and translational research. He has led teams that have delivered numerous small and large molecules into clinical development. Chris serves on the external review boards of the Long Island Bioscience Hub and the Alzheimer’s Drug Discovery Foundation. He earned his B.S. in biological sciences from Cornell University and his Ph.D. in molecular and cellular pharmacology from the State University of New York at Stony Brook before conducting postdoctoral training at SUNY Stony Brook.